Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma.

Journal Article (Journal Article)

BACKGROUND: The aim of this study was to prospectively examine the effects of hearing loss and posterior fossa syndrome (PFS), in addition to age at diagnosis and disease risk status, on change in intellectual and academic outcomes following diagnosis and treatment in a large sample of medulloblastoma patients. METHODS: Data from at least 2 cognitive and academic assessments were available from 165 patients (ages 3-21 years) treated with surgery, risk-adapted craniospinal irradiation, and 4 courses of chemotherapy with stem cell support. Patients underwent serial evaluation of cognitive and academic functioning from baseline up to 5 years post diagnosis. RESULTS: Serious hearing loss, PFS, younger age at diagnosis, and high-risk status were all significant risk factors for decline in intellectual and academic skills. Serious hearing loss and PFS independently predicted below-average estimated mean intellectual ability at 5 years post diagnosis. Patients with high-risk medulloblastoma and young age at diagnosis (<7 years) exhibited the largest drop in mean scores for intellectual and academic outcomes. CONCLUSIONS: Despite a significant decline over time, intellectual and academic outcomes remained within the average range at 5 years post diagnosis for the majority of patients. Future studies should determine if scores remain within the average range at time points further out from treatment. Patients at heightened risk should be closely monitored and provided with recommendations for appropriate interventions.

Full Text

Duke Authors

Cited Authors

  • Schreiber, JE; Gurney, JG; Palmer, SL; Bass, JK; Wang, M; Chen, S; Zhang, H; Swain, M; Chapieski, ML; Bonner, MJ; Mabbott, DJ; Knight, SJ; Armstrong, CL; Boyle, R; Gajjar, A

Published Date

  • August 2014

Published In

Volume / Issue

  • 16 / 8

Start / End Page

  • 1129 - 1136

PubMed ID

  • 24497405

Pubmed Central ID

  • PMC4096173

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou006


  • eng

Conference Location

  • England